- Home
- RRX vs EXEL Comparison
RRX vs EXEL Comparison
Compare RRX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RRX | EXEL |
|---|---|---|
| Founded | 1955 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.0B | 11.4B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | RRX | EXEL |
|---|---|---|
| Price | $206.45 | $44.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 21 |
| Target Price | ★ $210.70 | $46.50 |
| AVG Volume (30 Days) | 985.2K | ★ 2.1M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | 42.86 | ★ 57.95 |
| EPS | ★ 4.20 | 2.78 |
| Revenue | ★ $3,257,100,000.00 | $452,477,000.00 |
| Revenue This Year | $4.20 | $13.61 |
| Revenue Next Year | $12.13 | $13.13 |
| P/E Ratio | $50.07 | ★ $16.17 |
| Revenue Growth | ★ 5.21 | N/A |
| 52 Week Low | $105.96 | $33.76 |
| 52 Week High | $229.30 | $48.74 |
Technical Indicators
Market Signals| Indicator | RRX | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 52.94 |
| Support Level | $136.55 | $40.98 |
| Resistance Level | $216.03 | $46.66 |
| Average True Range (ATR) | 7.66 | 1.40 |
| MACD | 0.42 | -0.08 |
| Stochastic Oscillator | 52.11 | 33.25 |
Price Performance
Historical ComparisonAbout RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.